Transcriptomics and Epigenetics Analysis in Drug-Resistance of Multiple Myeloma
NCT ID: NCT05888636
Last Updated: 2024-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2019-06-18
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The prospective study will involve a patient cohort with MGUS, MM smouldering and MM, with the aim to characterize different transcriptional and epigenetic features, also including miRNAs, among MM cells susceptible or resistant to conventional therapies. The final goal is to identify new prognostic and predictive biomarkers that could be used as therapeutic tools to improve clinical targeted therapies.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
NCT00339963
Genomic-Based Diagnosis, Classification and Targeted Treatment of Multiple Myeloma
NCT01619358
Mutational Oncology in Clinical Practice
NCT06020625
Biochemical Role of Circulating microRNAs Expression as Diagnostic Markers for Non-Hodgkin's Lymphoma Patients
NCT05921812
Molecular Classification of Endometrial Cancer: Impact on Adjuvant Treatment Planning.
NCT06584630
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MGUS
ChIP-seq, NGS, ATAC-seq
Bone narrow sampling
MM smouldering
ChIP-seq, NGS, ATAC-seq
Bone narrow sampling
Syntomatic MM
ChIP-seq, NGS, ATAC-seq
Bone narrow sampling
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ChIP-seq, NGS, ATAC-seq
Bone narrow sampling
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Campus Bio-Medico University
OTHER
University of Rome Tor Vergata
OTHER
Sant'Eugenio Hospital, Rome
UNKNOWN
Regina Elena Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maurizio Fanciulli, PhD
Role: PRINCIPAL_INVESTIGATOR
IRCCS "Regina Elena" National Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Regina elena Cancer Institute
Roma, , Italy
"Regina Elena" National Cancer Institute
Rome, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RS1237
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.